2/25
10:35 am
fulc
Fulcrum Therapeutics move lower ‘overdone,' says Stifel [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics move lower ‘overdone,' says Stifel [Yahoo! Finance]
2/24
06:04 pm
fulc
Fulcrum Therapeutics (FULC) had its "outperform" rating reaffirmed by Leerink Partners.
Medium
Report
Fulcrum Therapeutics (FULC) had its "outperform" rating reaffirmed by Leerink Partners.
2/24
03:07 pm
fulc
Fulcrum Therapeutics (FULC) was given a new $17.00 price target by Truist Financial Corporation.
Medium
Report
Fulcrum Therapeutics (FULC) was given a new $17.00 price target by Truist Financial Corporation.
2/24
12:17 pm
fulc
Fulcrum Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
07:01 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
High
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
2/24
07:00 am
fulc
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
High
Report
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
2/17
08:00 am
fulc
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Low
Report
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
2/6
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/12
08:04 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $20.00 price target on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $20.00 price target on the stock.
1/9
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/7
08:00 am
fulc
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/21
07:42 am
fulc
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study [Yahoo! Finance]
Medium
Report
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study [Yahoo! Finance]
12/11
12:01 pm
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.
12/10
07:48 am
fulc
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
12/9
01:15 pm
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Bank of America Corporation from $6.00 to $7.00. They now have an "underperform" rating on the stock.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Bank of America Corporation from $6.00 to $7.00. They now have an "underperform" rating on the stock.
12/8
04:01 pm
fulc
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
High
Report
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
12/8
12:12 pm
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $25.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $25.00 price target on by analysts at Stifel Nicolaus.
12/8
11:02 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "underperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "underperform" rating reaffirmed by analysts at Citigroup Inc..
12/8
10:13 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "positive" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "positive" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
12/8
09:14 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/8
09:14 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
12/8
08:07 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at HC Wainwright from $18.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at HC Wainwright from $18.00 to $25.00. They now have a "buy" rating on the stock.
12/8
07:03 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/6
05:30 pm
fulc
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
High
Report
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
12/5
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)